Plain-English translation of NCT07554339 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a targeted drug that works against a specific gene mutation, combined with an immunotherapy called , can help people with advanced non-small cell lung cancer live longer without the cancer growing. You would have already completed chemotherapy and radiation before joining this trial. The study will compare people who receive the medication plus immunotherapy to those who receive a placebo (inactive pill) plus the same immunotherapy.
After standard chemotherapy and radiation, some advanced lung cancers continue to grow or come back. Researchers want to find out if adding this new targeted medication to existing immunotherapy can prevent the cancer from returning and help people survive longer.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new medication plus immunotherapy, or a placebo pill plus immunotherapy. Both groups receive the immunotherapy through an IV infusion, and you would take either the active medication or placebo by mouth at home. You would attend regular clinic visits for treatment, blood tests, and scans to monitor how well the treatment is working and check for side effects.
AI-generated summary from trial data · Oct 3, 2026 · Not medical advice
United States